University of Zurich Veterinary Hospital

University of Zurich — Division of Radiation Oncology · Switzerland

Ongoing European oncology clinical trial — listed by Oncowaf

What is being offered: Randomized therapeutic comparison of Lattice radiotherapy and SBRT for large inoperable canine tumors, or when radiotherapy is preferred to surgery. Five consecutive daily treatment sessions. Research biopsies are requested when safely accessible; the treating team confirms final eligibility and consent. Single enrolling center: University of Zurich Veterinary Hospital.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Large inoperable or rt preferred

Costs / coverage: 🟠 Partially funded. Owners pay the initial consultation, radiation-planning CT and anesthesia for the radiation treatments. Research funding covers the radiation itself and CT or MRI follow-up examinations at six and twelve months.

Contact: University of Zurich Radiation Oncology — +41 44 635 81 12

Official study / enrollment information →

Universitäres Tierspital Zürich / University of Zurich · Switzerland

Studienteilnahme möglich

What is being offered: Therapeutic surgical study comparing ICG and Angiostamp fluorescence guidance for canine brachial or lumbar plexus tumors; target enrollment40 dogs, ethics ZH026/2023. Suspected plexus tumor on CT/MRI and planned resection are sufficient for prescreening: cytology is helpful but explicitly not mandatory because sampling may be infeasible. PNST-specific; other soft-tissue sarcomas are not automatically eligible. Single enrolling center: University of Zurich Veterinary Hospital.

Who may qualify: Active tumor required; Planned surgery

Costs / coverage: 🟠 Partially funded. Research funding provides the study fluorescence dye free of charge. The primary protocol does not itemize coverage of staging, surgery or other care; confirm these costs with the Zurich study team.

Contact: University of Zurich Oncology — onkologie@vetclinics.uzh.ch

Official study / enrollment information →

University of Zurich Veterinary Hospital · Switzerland

Recruiting

What is being offered: Therapeutic surgical study comparing ICG and Angiostamp fluorescence guidance for dogs and cats with confirmed soft-tissue sarcoma requiring excision or re-excision after incomplete surgery. Surgery is adjusted to remove fluorescent residual tumor tissue. Severe cardiac/renal disease that prevents anesthesia excludes participation; final eligibility is investigator-confirmed. Single enrolling center: University of Zurich Veterinary Hospital. This general soft-tissue sarcoma cohort is distinct from the canine plexus/PNST cohort despite shared ethics identifier ZH026/2023.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned surgery

Costs / coverage: 🟠 Partially funded. Swiss National Science Foundation research funding covers the main part of the surgery cost. The exact percentage and coverage of staging, anesthesia, hospitalization and other care are not itemized publicly; confirm the owner-paid balance with the Zurich study team.

Contact: University of Zurich Oncology — onkologie@vetclinics.uzh.ch

Official study / enrollment information →

University of Zurich Veterinary Hospital · Switzerland

Participation currently possible on the University of Zurich study page

What is being offered: All enrolled dogs receive radiotherapy. Dogs are randomized to temozolomide plus lomustine or placebo to evaluate added chemotherapy for high-grade glioma.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation

Costs / coverage: The university states that biopsy, chemotherapy and study laboratory tests are covered and radiotherapy is discounted; confirm all costs directly.

Contact: University of Zurich Radiation Oncology — +41 44 635 81 12

Official study / enrollment information →

University of Zurich Veterinary Hospital · Switzerland

Participation currently possible on the University of Zurich study page

What is being offered: Current randomized study comparing FLASH and conventional proton radiotherapy for cats with oral squamous cell carcinoma, including tongue tumors. Radiation is given on three consecutive days at the Paul Scherrer Institute; cats remain hospitalized for four days at the University of Zurich Veterinary Hospital. Zurich handles enrollment and inpatient veterinary care; PSI is the radiation-delivery partner, not a separate owner-enrollment clinic. Initial CT and biopsy establish tumor extent/type; a temporary feeding tube is placed for treatment. Clinical follow-ups are weekly in month1 and every three months in year1, with CT at6,12,18 months. Final eligibility is confirmed by the study team.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation

Costs / coverage: 🟠 Partially funded. Owners pay half the initial diagnostic work-up cost: imaging, biopsy and blood tests. The official study flyer states that no further costs arise from the time of study enrollment. Confirm the current estimate and any unrelated care with the Zurich study team.

Contact: University of Zurich study team — Dr. Maximilian Körner; +41 44 635 95 55; onkologie@vetclinics.uzh.ch

Official study / enrollment information →